Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder.
• Pharmacological treatments for adult ADHD are continuously evolving.
• Viloxazine ER (Qelbree®) is a novel norepinephrine reuptake inhibitor and serotonin receptor modulator.

Purpose of the Study:

• To review the efficacy and safety of viloxazine ER for treating adult ADHD.
• To provide an overview of viloxazine ER's pharmacological properties.
• To assess viloxazine ER's role in the therapeutic landscape for adult ADHD.

Main Methods:

• Review of a randomized, double-blind, placebo-controlled, 6-week phase 3 trial.
• Analysis of viloxazine ER's impact on ADHD symptoms, severity, and executive function.
• Evaluation of safety and tolerability data in adult patients.

Main Results:

• Viloxazine ER significantly reduced ADHD symptoms and severity in adults.
• Improvements in executive function were observed.
• Treatment benefits were sustained for over 24 months.
• Viloxazine ER was generally well tolerated, with insomnia and headache as common adverse events.
• No clinically significant cardiovascular or hepatic adverse effects were noted.

Conclusions:

• Viloxazine ER is an effective and well-tolerated treatment option for adults with ADHD.
• It offers sustained symptom control and improved executive function.
• Viloxazine ER represents a valuable addition to the available therapeutic strategies for adult ADHD.